Core Insights - Both ImmunityBio (IBRX) and Moderna (MRNA) are biotech firms reliant on the successful commercialization of a single key drug while expanding their pipelines for future growth [1][2] Group 1: ImmunityBio (IBRX) - IBRX's sole marketed drug, Anktiva, is FDA-approved for treating BCG-unresponsive non-muscle invasive bladder cancer [3] - IBRX reported net product revenues of $113 million in 2025, reflecting a 700% year-over-year increase, driven by repeat prescriptions and a BCG shortage [4] - The company is pursuing label expansion for Anktiva, including a recent resubmission to the FDA for BCG-unresponsive NMIBC with papillary disease [5] - IBRX is exploring Anktiva's use in combination with therapies for various cancers, with recent regulatory approval in Saudi Arabia for non-small cell lung cancer [6] - The company's reliance on a single drug raises execution risks, especially following an FDA warning letter regarding misleading promotional claims for Anktiva [7][8] Group 2: Moderna (MRNA) - Moderna is transitioning from its COVID-19 vaccine success to a broader pipeline, with over 30 mRNA-based candidates in development [9][11] - The company plans to launch at least three to six new products by 2028, including an influenza vaccine and a personalized cancer therapy [12][13] - Despite strong growth, Moderna faces competitive pressure from larger pharmaceutical companies and remains heavily reliant on COVID-19 vaccine revenues [14] - Recent pipeline setbacks, such as the failure of an experimental CMV vaccine, highlight execution risks as the company diversifies its product portfolio [15] Group 3: Financial Estimates and Performance - The Zacks Consensus Estimate for IBRX suggests 77% sales growth in 2026, with a narrowing loss per share [16] - For Moderna, the 2026 sales estimate indicates 7% growth, with EPS expected to improve by over 6% [17] - Year-to-date, IBRX shares have increased by 273%, while MRNA shares have risen nearly 82%, compared to a 2% industry increase [18] - IBRX trades at a premium with a price/sales ratio of 29.67, compared to Moderna's 9.40 [20] Group 4: Investment Considerations - Both companies hold a Zacks Rank 3 (Hold), complicating the investment decision [22] - Moderna is viewed as a safer investment due to its diversified pipeline and financial flexibility, while IBRX's reliance on Anktiva raises concerns [23][25]

Core Insights - GSK's RSV vaccine, Arexvy, received FDA approval for expanded use in adults aged 18 to 49 years at higher risk of lower respiratory tract disease (LRTD) [1][3] - Year-to-date, GSK's shares have increased by 8.8%, outperforming the industry growth of 2.7% [2] - The FDA's approval was based on late-stage study data showing Arexvy's immune response comparable to that of adults aged 60 and older, with a consistent safety profile [3] Regulatory Approvals - The European Commission approved Arexvy for all adults aged 18 years and older to prevent RSV-related LRTD, expanding from previous approvals for those aged 60 and older and high-risk individuals aged 50 to 59 years [4] - GSK's regulatory application for Arexvy in China for adults aged 60 years and above has been accepted, with a final decision expected in 2027 [5] Market Context - With the recent FDA approval, Arexvy becomes the third FDA-approved RSV vaccine for younger adults, alongside Pfizer's Abrysvo and Moderna's mResvia [6] - Pfizer's Abrysvo is also approved for pregnant individuals, making it unique in providing maternal immunization to protect infants against RSV [10] - Moderna's mResvia is approved for older adults aged 60 years and above and for high-risk adults aged 18 to 59 years [11] Sales Performance - Arexvy recorded global sales of £0.6 billion in 2025, reflecting a 2% increase at constant exchange rates, driven by growth in ex-U.S. markets despite declining sales in the U.S. due to slower uptake among the 60-plus population [12]

Market Overview - Major indexes finished positively, with the Dow Jones Industrial Average gaining 0.5%, the S&P 500 up 0.8%, and the Nasdaq composite rising 1.3% [1][2] - The yield on the benchmark 10-year Treasury note increased by two basis points to 4.08% [1] - Crude oil prices rose, with West Texas Intermediate futures settling near $75.65 per barrel [1] Company Performances - Nvidia (NVDA) shares rose over 3% amid news that CEO Jensen Huang indicated the company may not invest further in OpenAI after its $30 billion stake [1] - Abercrombie & Fitch (ANF) reported earnings of $3.68 per share, exceeding expectations by 11 cents, but predicted only 2% sales growth due to tariffs, leading to a 5% drop in shares [1] - Broadcom (AVGO) is expected to report earnings of $2.03 per share, reflecting a 27% growth, with sales projected to rise 28% to $19.3 billion [1] - Ross Stores (ROST) shares jumped nearly 8% after reporting earnings of $2 per share on sales of $6.6 billion, surpassing forecasts [1] - Moderna (MRNA) surged over 8% after resolving a patent lawsuit, agreeing to pay a one-time fee of $950 million [1] Economic Indicators - The ADP reported that private payrolls rose by 63,000 in February, exceeding expectations of 43,000 [2] - The Federal Reserve's Beige Book indicated mixed economic activity across its 12 districts, with seven reporting increases and five showing flat to declining activity [1] Sector Movements - Tech stocks, particularly Nvidia and Tesla (TSLA), were among the winners, with Tesla gaining 1.1% after a previous decline [2] - Bitcoin surged 7% following President Trump's announcement regarding the Clarity Act, which is aimed at the crypto industry [1]

Core Viewpoint - Moderna's stock surged after settling a patent dispute with Arbutus Biopharma for $950 million, alleviating concerns over potential liabilities that could have reached $5 billion [1][1][1] Group 1: Settlement Details - The settlement involves a one-time payment of $950 million to Arbutus and Genevant Sciences, with no future royalties owed [1][1] - Moderna plans to appeal to the Federal Circuit court, claiming immunity as a government contractor; if unsuccessful, it may incur an additional payment of up to $1.3 billion within 90 days [1][1] - The settlement resolves all litigation related to Moderna's Covid vaccines, including Spikevax and mResvia, and addresses future litigation for next-generation vaccines mNexspike and mCombriax [1][1] Group 2: Financial Implications - Following the settlement, Moderna expects to end the year with $4.5 billion to $5 billion in cash and equivalents [1][1] - Analysts view the settlement as a positive development, reducing potential liquidity concerns and allowing Moderna to focus on upcoming late-stage oncology trials expected in 2026 [1][1] Group 3: Stock Performance - Moderna's stock rose 16% to close at $57.82 after the settlement announcement [1][1] - The stock has experienced volatility, previously rising 87% to a peak of $55.20 on January 22, then dropping 34% by February 11, before rebounding [1][1] - The stock currently holds a strong IBD Digital Relative Strength Rating of 97 out of a possible 99, indicating it ranks in the top 3% of all stocks for 12-month performance [1][1]

Core Viewpoint - Moderna, Inc. is experiencing significant developments following its settlement with Arbutus Biopharma and Genevant Sciences, which has positively influenced its stock performance and financial outlook [2][6] Group 1: Settlement Impact - The recent settlement with Arbutus Biopharma and Genevant Sciences resulted in a stock surge of over 10%, resolving all global patent litigation related to its Covid vaccines, including Spikevax and mResvia [2][6] - As part of the settlement, Moderna will pay a one-time fee of $950 million, ensuring no future royalties on these vaccines, which enhances the company's market position [2][6] Group 2: Legal Considerations - Despite the positive settlement, Moderna plans to appeal to the Federal Circuit court for immunity as a government contractor, which could potentially save the company up to $1.3 billion if successful [3][6] - No accrual has been recorded for the potential additional payment, as the loss is not considered probable, highlighting the complexities of patent disputes in the pharmaceutical industry [3] Group 3: Financial Outlook - Following the settlement, Moderna expects to end the year with cash reserves between $4.5 billion and $5 billion, which is crucial for ongoing research and development efforts [4][6] - The resolution of the patent dispute provides a more predictable path for future growth, particularly for next-generation vaccines like mNexspike and mCombriax [4] Group 4: Stock Performance - Currently, Moderna's stock is trading at $49.83, reflecting a decrease of approximately 5.71% for the day, with a market capitalization of approximately $19.47 billion [5]

Core Viewpoint - Moderna's shares increased by approximately 4% following the EMA's CHMP recommendation for marketing authorization of its mRNA-based combination vaccine, mCombriax, targeting COVID-19 and influenza [1][9]. Group 1: Regulatory Approval Process - The CHMP's recommendation will be reviewed by the European Commission, with a final decision anticipated soon [2]. - If approved, mCombriax will be Moderna's fourth marketed product in the EU, following two COVID-19 vaccines and an RSV vaccine [2]. Group 2: Clinical Study Results - The recommendation was supported by data from a pivotal phase III study that met its primary endpoints, showing that a single dose of mCombriax produced higher immune responses against COVID-19 and influenza compared to standalone vaccines [3][9]. - The study involved around 8,000 adults, split into two age cohorts: one for adults aged 65 and older and another for those aged 50 to 64, comparing mCombriax with existing influenza vaccines [4]. Group 3: Stock Performance - Year-to-date, Moderna's stock has surged approximately 82%, significantly outperforming the industry average growth of 10% [7]. Group 4: Product Details and Future Filings - mCombriax combines Moderna's mNexspike and mRNA-1010, an investigational influenza vaccine, with regulatory filings currently under review in multiple regions including the US, Europe, Canada, and Australia [8]. - A final decision by the FDA regarding mCombriax is expected by August 5, 2026 [8]. Group 5: FDA Review and Challenges - Moderna had previously submitted a regulatory filing for mCombriax to the FDA, which was voluntarily withdrawn in May 2025 due to requests for additional efficacy data for the flu component [10]. - The FDA initially refused to review the mRNA-1010 filing but later reversed its decision after Moderna proposed an age-based regulatory pathway for approval [11].

Core Viewpoint - Moderna's shares increased by 6% following the FDA's decision to review its regulatory filing for the seasonal influenza vaccine, mRNA-1010, with a final decision expected by August 5, 2026 [1][8]. Group 1: Regulatory Developments - The FDA had previously refused to review the mRNA-1010 filing, citing inadequacies in the late-stage study that compared it to a standard-dose influenza vaccine [2]. - Moderna has modified its regulatory filing to seek full approval for adults aged 50-64 and accelerated approval for those aged 65 and above [2][4]. - The filing is supported by data from multiple late-stage studies demonstrating that mRNA-1010 generates immune responses comparable to existing flu vaccines from GSK and Sanofi [4]. Group 2: Market Implications - If approved, Moderna plans to commercially launch mRNA-1010 for the 2026/2027 vaccination season and will conduct additional studies for older adults as part of post-marketing requirements [3]. - The FDA's reversal is seen as a significant step in expanding Moderna's product portfolio beyond its COVID-19 vaccine and RSV vaccine [5]. Group 3: Future Prospects - The recent developments have also raised optimism for mRNA-1083, a combination vaccine for COVID-19 and influenza, which is awaiting further guidance from the FDA [6]. - Year-to-date, Moderna's stock has increased by 58%, significantly outperforming the industry growth of 9% [7].

Core Insights - Moderna reported a loss of $2.11 per share in Q4 2025, which is an improvement compared to the Zacks Consensus Estimate of a loss of $2.60 and a loss of $2.91 in the same quarter last year [1][6] - Total revenues for the quarter were $678 million, exceeding the Zacks Consensus Estimate of $659.5 million, but reflecting a 30% decline year over year due to lower net product sales [1][3] - Year-to-date, Moderna's stock has increased by 26%, outperforming the industry growth of 18% [1] Financial Performance - Overall product sales decreased by 31% year over year to $645 million, primarily due to reduced sales volume of COVID-19 vaccines [3] - The company generated $33 million from grants, collaborations, licensing, and royalty revenues, marking an 18% increase year over year [4] - For the full year 2025, Moderna's total revenues were $1.94 billion, down 40% year over year, with a loss of $7.26 per share, which is an improvement from a loss of $9.28 per share in the previous year [7] Cost Management - Selling, general and administrative (SG&A) expenses were $308 million, down 12% year over year due to reductions in consulting and external services [5] - Research and development (R&D) expenses decreased by 31% to $775 million, reflecting prioritization and efficiency in clinical development [5] Future Guidance - Moderna expects total revenues to grow by up to 10% in 2026 compared to 2025 levels, with a revenue split nearly equal between domestic and international operations [8] - The company is targeting operating expenses of approximately $4.9 billion, including $3 billion for R&D and $1 billion for SG&A [8] - Capital expenditure is projected to be between $0.2 billion and $0.3 billion [8] - Moderna anticipates ending 2026 with cash and cash equivalents between $5.5 billion and $6.0 billion [9] Pipeline Developments - Moderna is developing over 30 mRNA-based investigational candidates across various clinical stages, including a late-stage study for a norovirus vaccine [10] - The company faced a setback when the FDA refused to review its filing for a seasonal flu vaccine due to inadequacies in the supporting study [11] - An important candidate in the pipeline is intismeran autogene, a personalized cancer therapy being evaluated in collaboration with Merck across multiple pivotal studies [12][13]

Core Insights - The fourth-quarter earnings season is ongoing, with major pharmaceutical companies set to announce their results, including AstraZeneca, Incyte, Gilead Sciences, Vertex Pharmaceuticals, and Moderna [1] Industry Overview - Several large pharmaceutical companies such as Johnson & Johnson, Lilly, AbbVie, Biogen, Merck, and Amgen reported better-than-expected fourth-quarter results, surpassing estimates for both earnings and revenues. In contrast, Novartis and Sanofi had mixed results, with earnings exceeding estimates but revenues falling short [2] - As of February 4, 40% of companies in the Medical sector, representing 73.9% of the sector's market capitalization, reported quarterly earnings. Among these, 87.5% exceeded earnings estimates, and 75% surpassed revenue estimates. Year-over-year, earnings increased by 3.3%, while revenues rose by 9.5%. Overall, fourth-quarter earnings for the Medical sector are expected to decline by 1.5%, while sales are projected to increase by 9.1% compared to the previous year [3] Company-Specific Insights AstraZeneca - AstraZeneca's performance has been mixed, with earnings beating estimates in two of the last four quarters, meeting once, and missing once, resulting in an average surprise of 3.81%. The consensus estimate for fourth-quarter sales is $15.78 billion, with earnings expected at $2.18 per share [5] - Key medicines, particularly cancer drugs and diabetes medicine, are expected to drive fourth-quarter sales, supported by strong demand trends [7] - AstraZeneca is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [8] Incyte - Incyte has a mixed history of earnings surprises, beating estimates in three of the last four quarters, with an average surprise of 14.35%. The consensus estimate for fourth-quarter sales is $1.35 billion, with earnings expected at $1.94 per share [9] - Strong sales of Jakafi and expected growth in Opzelura sales are likely to contribute to revenue growth in the fourth quarter [11][12] - Incyte is also set to report its fourth-quarter and full-year 2025 earnings on February 10 [12] Gilead Sciences - Gilead Sciences has a mixed earnings surprise history, beating estimates in three of the last four quarters, with an average surprise of 7.80%. The consensus estimate for fourth-quarter sales is $7.57 billion, with earnings expected at $1.83 per share [13] - Increased sales from Biktarvy and Descovy, along with growth in the Liver Disease portfolio, are anticipated to drive top-line growth [14] - Gilead is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [15] Vertex Pharmaceuticals - Vertex has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.01%. The consensus estimate for fourth-quarter sales is $3.17 billion, with earnings expected at $5.07 per share [16] - Revenue growth is likely to be driven by higher sales of its cystic fibrosis medicine, Trikafta, and contributions from newer drugs [18] - Vertex is set to report its fourth-quarter and full-year 2025 results on February 12 [19] Moderna - Moderna has a strong earnings surprise history, beating estimates in all of the last four quarters, with an average surprise of 31.45%. The consensus estimate for fourth-quarter sales is $661.4 million, with expected earnings showing a loss of $2.60 per share [20] - Revenue is expected to be primarily driven by sales of COVID-19 vaccines, although demand has declined recently [22] - Moderna is scheduled to report its fourth-quarter and full-year 2025 earnings on February 13 [23]

Core Insights - Moderna is expected to exceed expectations in its fourth-quarter and full-year 2025 results, with earnings having previously beaten estimates by 76.28% in the last quarter [1] - The Zacks Consensus Estimate for sales is $661.4 million, with an anticipated loss of $2.60 per share [1] Product Portfolio and Sales Expectations - Moderna has three marketed products: two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia), with overall product sales estimated at $627 million, primarily driven by COVID-19 vaccines [2] - Minimal sales are expected from the RSV vaccine due to strong competition from GSK and Pfizer [3] Pipeline Developments - A key candidate in Moderna's pipeline is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, showing promising results in a mid-stage study for high-risk melanoma [4] - Intismeran is currently being evaluated in three pivotal phase III studies, with additional mid-stage studies for other cancer types [5] - Investors are keen on updates regarding the progress of intismeran and other pipeline candidates [5] Combination Vaccine and Regulatory Updates - Moderna's mRNA-1083, a COVID-19/influenza combination vaccine, is on track for FDA resubmission after addressing efficacy data concerns [6] - Positive late-stage data for the standalone flu shot, mRNA-1010, supports the efficacy of the combination vaccine [6] Earnings Performance and Stock Movement - Moderna has consistently beaten earnings estimates over the past four quarters, with an average surprise of 31.45% [7] - Over the past year, Moderna's shares have increased by nearly 29%, compared to the industry's 39% growth [8] Earnings Prediction - The model predicts an earnings beat for Moderna, with an Earnings ESP of +3.16% and a more accurate estimate of a loss of $2.52 per share compared to the consensus estimate of a loss of $2.60 [11][12]